Vaccine response and aging in people with HIV
Part of Immune system & allergy, Infections clinical trials.
This study is for people living with HIV who are 18 or older and on HIV medication. Researchers want to learn how the immune system and vaccine response change as people age, and will give a pneumococcal (pneumonia) vaccine to study that.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have HIV and are taking HIV medications
- Your HIV viral load has been under 200 in the last year
- You do not have another serious condition that weakens the immune system
- You are not pregnant at the start of the study
- You are able and willing to have blood drawn and follow the study schedule
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is looking at how age affects the immune system's response to a pneumococcal vaccine. Researchers want to compare younger and older adults to see if immune cells change with age.
This study tests a new pneumococcal vaccine (PCV26) for safety in adults 60 and older. It aims to find out if the vaccine is safe and how the body responds to it.
This trial studies how safe and how well the body’s immune system responds to meningococcal and pneumococcal vaccines in adults living with HIV. It may help confirm these vaccines work properly and are safe for people on HIV treatment.
This trial tests a newer pneumonia vaccine (PCV21) in older veterans with weakened immune systems who have already received an older pneumonia vaccine (PPSV23). It aims to see if the new vaccine provides better protection.
This study tests a new pneumococcal vaccine (PCV15) to see how well it protects against carrying the bacteria that can cause pneumonia. Healthy adults aged 18–50 who have not had a pneumococcal vaccine in the last 5 years may join.
This trial tests a catch-up pneumococcal vaccine for children and adolescents who may have missed some doses. It aims to see how safe and effective the vaccine is in healthy kids aged 15 months to 17 years.
Hear when a new HIV Infections trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.